PARP1 and acute myeloid leukemia: Regarding metabolic intervention, the arginine deprivation agent ADI-PEG20 specifically kills leukemia cells (124); the ASCT2 inhibitor V-9302 selectively kills AML cells by blocking glutamine uptake while maintaining the metabolic requirements of T cells (125); and APO866 inhibits PARP activity by depleting NAD+ and, in concert with Olaparib, causes HR-deficient AML cell death.